Edwards Lifesciences (EW) Tops Q1 EPS by 12c, Narrows FY 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Edwards Lifesciences (EW) PT Raised to $118 at Stifel
April 26, 2017 8:36 AM EDTStifel raised its price target on Edwards Lifesciences (NYSE: EW) to $118.00 (from $114.00) while maintaining a Buy rating. 1Q17 EPS of $0.94 beat consensus projections by $0.12. The quarters impressive EPS beat was driven by broad based top-line outperformance across the companys product lines and... More
